Heidi E Kosiorek

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4622624/publications.pdf

Version: 2024-02-01

623734 580821 53 692 14 25 citations g-index h-index papers 53 53 53 869 citing authors docs citations times ranked all docs

#	Article	IF	CITATIONS
1	Association of Therapy for Autoimmune Disease With Myelodysplastic Syndromes and Acute Myeloid Leukemia. JAMA Oncology, 2017, 3, 936.	7.1	90
2	Contrast-Enhanced Spectral Mammography is Comparable to MRI in the Assessment of Residual Breast Cancer Following Neoadjuvant Systemic Therapy. Annals of Surgical Oncology, 2018, 25, 1350-1356.	1.5	80
3	Symptomatic Profiles of Patients With Polycythemia Vera: Implications of Inadequately Controlled Disease. Journal of Clinical Oncology, 2016, 34, 151-159.	1.6	56
4	Assessing tumor extent on contrast-enhanced spectral mammography versus full-field digital mammography and ultrasound. Clinical Imaging, 2017, 46, 78-84.	1.5	46
5	Phase 2 study of ruxolitinib and decitabine in patients with myeloproliferative neoplasm in accelerated and blast phase. Blood Advances, 2020, 4, 5246-5256.	5. 2	45
6	Proton beam therapy reirradiation for breast cancer: Multiâ€institutional prospective PCG registry analysis. Breast Journal, 2019, 25, 1160-1170.	1.0	29
7	Patient outcomes from lung cancer and diabetes mellitus: a matched case–control study. Future Science OA, 2018, 4, FSO248.	1.9	25
8	Value Added of Preoperative Contrast-Enhanced Digital Mammography in Patients With Invasive Lobular Carcinoma of the Breast. Clinical Breast Cancer, 2018, 18, e1339-e1345.	2.4	23
9	Representation of Women as Editors in Anesthesiology Journals. Anesthesia and Analgesia, 2022, 134, 956-963.	2.2	23
10	Breast MRI phenotype and background parenchymal enhancement may predict tumor response to neoadjuvant endocrine therapy. Breast Journal, 2018, 24, 1010-1014.	1.0	22
11	Same-day Discharge Is Safe and Effective After Implant-Based Breast Reconstruction. Annals of Plastic Surgery, 2021, 87, 144-149.	0.9	20
12	Co-Existing Prostate Cancer and Diabetes Mellitus: Implications for Patient Outcomes and Care. Endocrine Practice, 2017, 23, 816-821.	2.1	19
13	Survival and glycemic control outcomes among patients with coexisting pancreatic cancer and diabetes mellitus. Future Science OA, 2018, 4, FSO291.	1.9	16
14	Capsular contracture in the modern era: A multidisciplinary look at the incidence and risk factors after mastectomy and implant-based breast reconstruction. American Journal of Surgery, 2021, 221, 1005-1010.	1.8	15
15	Symptom burden and quality of life in patients with high-risk essential thrombocythaemia and polycythaemia vera receiving hydroxyurea or pegylated interferon alfa-2a: a post-hoc analysis of the MPN-RC 111 and 112 trials. Lancet Haematology,the, 2022, 9, e38-e48.	4.6	15
16	Survival and glycemic control in patients with colorectal cancer and diabetes mellitus. Future Science OA, 2018, 4, FSO335.	1.9	14
17	Early post-transplantation factors predict survival outcomes in patients undergoing allogeneic hematopoietic cell transplantation for myelofibrosis. Blood Cancer Journal, 2020, 10, 36.	6.2	14
18	Evaluation of NUC-1031: a first-in-class ProTide in biliary tract cancer. Cancer Chemotherapy and Pharmacology, 2020, 85, 1063-1078.	2.3	14

#	Article	IF	CITATIONS
19	Glycemic control and survival of patients with coexisting diabetes mellitus and gastric or esophageal cancer. Future Science OA, 2019, 5, FSO397.	1.9	11
20	International Normalized Ratio Does Not Predict Gastrointestinal Bleeding After Endoscopic Retrograde Cholangiopancreatography in Patients With Cirrhosis. Gastroenterology Research, 2017, 10, 177-181.	1.3	10
21	Treatment of Myelofibrosis Patients with the TGF- \hat{l}^2 1/3 Inhibitor AVID200 (MPN-RC 118) Induces a Profound Effect on Platelet Production. Blood, 2021, 138, 142-142.	1.4	10
22	Patient Perspectives Regarding Allogeneic Bone Marrow Transplantation in Myelofibrosis. Biology of Blood and Marrow Transplantation, 2019, 25, 398-402.	2.0	8
23	Gauging the efficacy of neoadjuvant endocrine therapy in breast cancer patients with known axillary disease. Journal of Surgical Oncology, 2020, 122, 619-622.	1.7	8
24	Circulating Cell-Free Tumor DNA in Advanced Pancreatic Adenocarcinoma Identifies Patients With Worse Overall Survival. Frontiers in Oncology, 2021, 11, 794009.	2.8	8
25	Survival and glycemic control in patients with coexisting melanoma and diabetes mellitus. Future Science OA, 2019, 5, FSO368.	1.9	7
26	Implications of neuroendocrine tumor and diabetes mellitus on patient outcomes and care: a matched case–control study. Future Science OA, 2021, 7, FSO684.	1.9	6
27	Synergistic combination of cytotoxic chemotherapy and cyclinâ€dependent kinase 4/6 inhibitors in biliary tract cancers. Hepatology, 2022, 75, 43-58.	7.3	6
28	Evaluation of Therapeutic Strategies to Reduce the Number of Thrombotic Events in Patients With Polycythemia Vera and Essential Thrombocythemia. Frontiers in Oncology, 2020, 10, 636675.	2.8	5
29	Item nonresponse on the Myeloproliferative Neoplasms Symptom Assessment Form (MPN-SAF): a comparison of missing data strategies. Leukemia and Lymphoma, 2019, 60, 1789-1795.	1.3	4
30	Feasibility of Oophorectomy at the Time of Vaginal Hysterectomy in Patients with Pelvic Organ Prolapse. Journal of Minimally Invasive Gynecology, 2019, 26, 1063-1069.	0.6	4
31	Mortality and glycemic control among patients with diabetes mellitus and uterine or ovarian cancer. Future Science OA, 2021, 7, FSO670.	1.9	4
32	Survival and glycemic control in patients with co-existing squamous cell carcinoma and diabetes mellitus. Future Science OA, 2021, 7, FSO683.	1.9	4
33	FGFR2-IIIb Expression by Immunohistochemistry Has High Specificity in Cholangiocarcinoma with FGFR2 Genomic Alterations. Digestive Diseases and Sciences, 2022, 67, 3797-3805.	2.3	4
34	Quality of life independently predicts overall survival in myelofibrosis: Key insights from the COntrolled MyeloFibrosis Study with ORal Janus kinase inhibitor Treatment ⟨scp⟩(COMFORT)â€i⟨scp⟩ study. British Journal of Haematology, 2022, 198, 1065-1068.	2.5	4
35	Relation of Telemetry Use and Mortality Risk, Hospital Length of Stay, and Readmission Rates in Patients With Respiratory Illness. American Journal of Cardiology, 2017, 120, 1416-1420.	1.6	3
36	Validation of a Modified Version of the Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score. Journal of Hematology (Brossard, Quebec), 2021, 10, 207-211.	1.0	3

#	Article	IF	Citations
37	Assessing the relationship between institutional cancer and diabetes mortality rates using National Death Index data. Future Science OA, 2020, 6, FSO633.	1.9	2
38	Survival and glycemic control in patients with coexisting lymphoma and diabetes: a case–control analysis. Future Science OA, 2021, 7, FSO641.	1.9	2
39	Does Prior Breast Augmentation Affect Outcomes After Mastectomy With Reconstruction? An Analysis of Postoperative Complications and Reoperations. Annals of Plastic Surgery, 2021, 86, 508-511.	0.9	2
40	Photodynamic Therapy in Refractory Mycosis Fungoides: A Prospective, Open-Label Study. Blood, 2020, 136, 32-32.	1.4	2
41	Clinical Trial Design Features of Myelofibrosis Trials during the Last Decade: Comprehensive Review of Clinicaltrials.Gov Data 2010-2019. Blood, 2020, 136, 37-37.	1.4	2
42	Patient-Awareness Survey: Do Breast Implants Affect the Acquisition and Accuracy of Screening Mammography?. Journal of Breast Imaging, 2019, 1, 297-302.	1.3	1
43	Depomedroxyprogesterone acetate therapy for hot flashes in survivors of breast cancer: no unfavorable impact on recurrence and survival. Supportive Care in Cancer, 2020, 28, 2139-2143.	2.2	1
44	Mortality and glycemic control among patients with acute and chronic myeloid leukemia and diabetes: a case–control study. Future Science OA, 2021, 7, FSO639.	1.9	1
45	Unplanned implant removal in locally advanced breast cancer. Breast Journal, 2021, 27, 466-471.	1.0	1
46	Impact of COVID19 Pandemic on an International MPN Patient Population: Survey Results from 1560 MPN Patients. Blood, 2020, 136, 1-3.	1.4	1
47	Improving the Definition of Response Assessment: Prognostic Value of Minimal Residual Disease Combined with PET/CT at Day 100 Post Autologous Stem Cell Transplantation in Multiple Myeloma. Blood, 2020, 136, 33-34.	1.4	1
48	Validation of a Modified Version of the Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score (MPN-SAF TSS). Blood, 2020, 136, 26-26.	1.4	1
49	Single-Cell Multi-Omics Reveals That Pegylated Interferon-Alfa Treatment Differentially Redirects Mutated and Wildtype Hematopoietic Cell Differentiation Trajectories in CALR-mutated Essential Thrombocythemia (ET) Patients. Blood, 2021, 138, 57-57.	1.4	0
50	An Inpatient COVID-19 Prophylaxis Protocol and Its Outcomes: Adherence and Efficacy. Blood, 2021, 138, 4267-4267.	1.4	0
51	Analysis of Free-Text Responses in an International Myeloproliferative Neoplasms Patient Survey to Assess Impact of the COVID-19 Pandemic on Clinical Care. Blood, 2020, 136, 11-12.	1.4	0
52	Relationship of Area-Level Socioeconomic Status Indicators and Nutritional Anemias: Analysis of Folate, Vitamin B12, and Iron Deficiencies. Blood, 2020, 136, 16-17.	1.4	0
53	Symptom Burden and Quality of Life in High-Risk Essential Thrombocythemia and Polycythemia Vera Patients Receiving Hydroxyurea or Pegylated Interferon Alfa-2a: Results of Myeloproliferative Neoplasms Research Consortium (MPN-RC) 111 and 112 Trials. Blood, 2020, 136, 19-21.	1.4	0